Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment

References

• Kantarjian H, O’Brien S, Cortes J et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer113, 1933–1952 (2008).
   PubMed Web of Science ®Google Scholar
• Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br. J. Haematol.132(1), 3–12 (2006).
   PubMed Web of Science ®Google Scholar
• Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr. Opin. Infect. Dis.22, 403–409 (2009).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case–control observational study of 27 recent cases. J. Infect. Dis.191, 1350–1360 (2005).
   PubMed Web of Science ®Google Scholar
• Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant.39, 425–429 (2007).
   PubMed Web of Science ®Google Scholar
• Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin. Microbiol. Rev.13(2), 236–301 (2000).
   PubMed Web of Science ®Google Scholar
• Bethge WA, Schmalzing M, Stuhler G et al. Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. Haematol.90, ECR22 (2005).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.34(7), 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis.41(5), 634–653 (2005).
   PubMed Web of Science ®Google Scholar
• Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J. Clin. Oncol.19, 253–259 (2001).
   PubMed Web of Science ®Google Scholar
• Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin. Infect. Dis.46(11), 1733–1737 (2008).
   PubMed Web of Science ®Google Scholar
• Tarrand JJ, Lichterfeld M, Warraich I et al. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am. J. Clin. Pathol.119, 854–858 (2003).
   PubMed Web of Science ®Google Scholar
• Bialek R, Konrad F, Kern J et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J. Clin. Pathol.58, 1180–1184 (2005).
   PubMed Web of Science ®Google Scholar
• Rickerts V, Mousset S, Lambrecht E et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin. Infect. Dis.44(8), 1078–1083 (2007).
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C, Resch G, Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin. Infect. Dis.45(7), e101–e104 (2007).
   PubMed Web of Science ®Google Scholar
• Bodey GP. Infectious complications of acute leukemia. Med. Times94(9), 1076–1085 (1966).
   PubMedGoogle Scholar
• Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Iron and infection: the heart of the matter. FEMS Immunol. Med. Microbiol.43, 325–330 (2005).
   PubMedGoogle Scholar
• Maertens J, Demuynck H, Verbeken EK et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant.24, 307–312 (1999).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood100, 4358–4366 (2002).
   PubMed Web of Science ®Google Scholar
• Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis.32, 1319–1324 (2001).
   PubMed Web of Science ®Google Scholar
• Martino R, Subirá M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br. J. Haematol.116, 475–482 (2002).
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood102, 827–833 (2003).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis.45(9), 1161–1170 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin. Infect. Dis.47, 1041–1050 (2008).
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis.48, 265–273 (2009).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis.50, 1091–1100 (2010).
   PubMed Web of Science ®Google Scholar
• Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica86(8), 862–870 (2001).
   PubMed Web of Science ®Google Scholar
• Nosari A, Oreste P, Montillo M et al. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica85(10), 1068–1071 (2000).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica91(8), 1068–1075 (2006).
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med.350, 950–952 (2004).
   PubMed Web of Science ®Google Scholar
• Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg. Infect. Dis.15(9), 1395–1401 (2009).
   PubMed Web of Science ®Google Scholar
• Rüping MJ, Heinz WJ, Kindo AJ et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J. Antimicrob. Chemother.65(2), 296–302 (2010).
   PubMed Web of Science ®Google Scholar
• Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica89, 207–214 (2004).
   PubMed Web of Science ®Google Scholar
• Pagano L, Valentini CG, Posteraro B et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J. Chemother.21, 322–329 (2009).
   PubMed Web of Science ®Google Scholar
• Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int. J. Infect. Dis.14(Suppl. 3), e100–e103 (2010).
   PubMed Web of Science ®Google Scholar
• Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg. Infect. Dis.16(9), 1456–1458 (2010).
   PubMed Web of Science ®Google Scholar
• Meis JF, Chakrabarti A. Changing epidemiology of an emerging infection: zygomycosis. Clin. Microbiol. Infect.15(Suppl. 5), 10–14 (2009).
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Das A, Mandal J et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol.44(4), 335–342 (2006).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin. Infect. Dis.44(8), 1089–1090 (2007).
   PubMed Web of Science ®Google Scholar
• Diwakar A, Dewan RK, Chowdhary A, Randhawa HS, Khanna G, Gaur SN. Zygomycosis–a case report and overview of the disease in India. Mycoses50(4), 247–254 (2007).
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Das A, Sharma A et al. Ten years’ experience in zygomycosis at a tertiary care centre in India. J. Infect.42(4), 261–266 (2001).
   PubMed Web of Science ®Google Scholar
• Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin. Microbiol. Infect. DOI: 10.1111/j.1469–0691.2010.03456.x. (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Kara IO, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with haematologic malignancies. Int. J. Clin. Pract.63(1), 134–139 (2009).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Roilides E, Chiou CC et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr. Infect. Dis. J.26(8), 723–727 (2007).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin. Infect. Dis.30, 851–856 (2000).
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin. Infect. Dis.47, 503–509 (2008).
   PubMed Web of Science ®Google Scholar
• Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr. Opin. Investig. Drugs.4, 179–185 (2003).
   PubMedGoogle Scholar
• Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto). Br. J. Haematol.99, 331–336 (1997).
   PubMed Web of Science ®Google Scholar
• Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother.46(5), 1581–1582 (2002).
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Mullane K, van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother.50, 126–133 (2006).
   PubMed Web of Science ®Google Scholar
• van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis.42, e61–e65 (2006).
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino–orbital–cerebral mucormycosis. Clin. Infect. Dis.47, 364–371 (2008).
   PubMed Web of Science ®Google Scholar
• Price TH, Bowden RA, Boeckh M et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood95(11), 3302–3309 (2000).
   PubMed Web of Science ®Google Scholar
• Mousset S, Hermann S, Klein SA et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann. Hematol.84(11), 734–741 (2005).
   PubMed Web of Science ®Google Scholar
• John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin. Microbiol. Infect.11(7), 515–517 (2005).
   PubMed Web of Science ®Google Scholar
• Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob. Agents Chemother.50(11), 3968–3969 (2006).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev.20(4), 695–704 (2007).
   PubMed Web of Science ®Google Scholar
• Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J. Infect.28(Suppl. 1), 7–15 (1994).
   PubMedGoogle Scholar
• Nucci M, Marr KA, Queiroz-Telles F et al.Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.38(9), 1237–1242 (2004).
   PubMed Web of Science ®Google Scholar
• Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J. Infect.60(5), 331–337 (2010).
   PubMed Web of Science ®Google Scholar
• Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection36(4), 296–313 (2008).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br. J. Haematol.111(1), 272–276 (2000).
   PubMed Web of Science ®Google Scholar
• Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood90(3), 999–1008 (1997).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz-Telles F et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer98(2), 315–319 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis.26(6), 1383–1396 (1998).
   PubMed Web of Science ®Google Scholar
• Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin. Infect. Dis.40(Suppl. 6), S401–S408 (2005).
   PubMed Web of Science ®Google Scholar
• Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis.42(10), 1398–1403 (2006).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis.36(9), 1122–1131 (2003).
   PubMed Web of Science ®Google Scholar
• Azor M, Gené J, Cano J, Guarro J. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob. Agents Chemother.51(4), 1500–1503 (2007).
   PubMed Web of Science ®Google Scholar
• Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob. Agents Chemother.46(10), 3298–3300 (2002).
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Prigitano A, Dho G et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob. Agents Chemother.52(7), 2683–2685 (2008).
   PubMed Web of Science ®Google Scholar
• Lortholary O, Obenga G, Biswas P et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob. Agents Chemother.54(10), 4446–4450 (2010).
   PubMed Web of Science ®Google Scholar
• Hsiue HC, Ruan SY, Kuo YL, Huang YT, Hsueh PR. Invasive infections caused by non-Aspergillus moulds identified by sequencing analysis at a tertiary care hospital in Taiwan, 2000–2008. Clin. Microbiol. Infect.16(8), 1204–1206 (2010).
   PubMed Web of Science ®Google Scholar
• Dignani MC, Anaissie E. Human fusariosis. Clin. Microbiol. Infect.10(Suppl. 1), 67–75 (2004).
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Stratton SL, Dignani MC et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood101(7), 2542–2546 (2003).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Perfect JR. Scedosporium species infections and treatments. J. Chemother.15(Suppl. 2), 16–27 (2003).
   PubMed Web of Science ®Google Scholar
• Berenguer J, Rodríguez-Tudela JL, Richard C et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine.76(4), 256–265 (1997).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med. Mycol.47(4), 359–370 (2009).
   PubMed Web of Science ®Google Scholar
• Caira M, Girmenia C, Valentini CG et al. Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. Haematol.93(1), 104–110 (2008).
   PubMed Web of Science ®Google Scholar
• Idigoras P, Pérez-Trallero E, Piñeiro L et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990–1999. Clin. Infect. Dis.32(11), E158–E165 (2001).
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Bodey GP, Tarrand JJ, Raad II, Kontoyiannis DP. The significance of blood cultures positive for emerging saprophytic moulds in cancer patients. Clin. Microbiol. Infect.10(10), 922–925 (2004).
   PubMed Web of Science ®Google Scholar
• Kimura M, Maenishi O, Ito H, Ohkusu K. Unique histological characteristics of Scedosporium that could aid in its identification. Pathol. Int.60(2), 131–136 (2010).
   PubMed Web of Science ®Google Scholar
• Cortez KJ, Roilides E, Quiroz-Telles F et al. Infections caused by Scedosporium spp. Clin. Microbiol. Rev.21(1), 157–197 (2008).
   PubMed Web of Science ®Google Scholar
• Castelli MV, Buitrago MJ, Bernal-Martinez L, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J. Clin. Microbiol.46(10), 3412–3416 (2008).
   PubMed Web of Science ®Google Scholar
• Malloch D, Salkin IA. A new species of Scedosporium associated with osteomyelitis in humans. Mycotaxon21, 247–255 (1984).
   Web of Science ®Google Scholar
• Wright JH. A case of Madura foot. J. Boston Soc. Med. Sci.2(8), 128–130.1 (1898).
   PubMedGoogle Scholar
• Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989–2006. Clin. Infect. Dis.43(12), 1580–1584 (2006).
   PubMed Web of Science ®Google Scholar
• Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg. Infect. Dis.13(8), 1170–1177 (2007).
   PubMed Web of Science ®Google Scholar
• Husain S, Muñoz P, Forrest G et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin. Infect. Dis.40(1), 89–99 (2005).
   PubMed Web of Science ®Google Scholar
• Tintelnot K, Just-Nübling G, Horré R et al. A review of German Scedosporium prolificans cases from 1993 to 2007. Med. Mycol.47(4), 351–358 (2009).
   PubMed Web of Science ®Google Scholar
• Grenouillet F, Botterel F, Crouzet J et al.Scedosporium prolificans: an emerging pathogen in France? Med. Mycol.47(4), 343–350 (2009).
   PubMed Web of Science ®Google Scholar
• Heath CH, Slavin MA, Sorrell TC. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin. Microbiol. Infect.15(7), 689–693 (2009).
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE; EUROFUNG Network. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother.46(1), 62–68 (2002).
   PubMed Web of Science ®Google Scholar
• Gilgado F, Serena C, Cano J, Gené J, Guarro J. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob. Agents Chemother.50(12), 4211–4213 (2006).
   PubMed Web of Science ®Google Scholar
• Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob. Agents Chemother.52(5), 1743–1750 (2008).
   PubMed Web of Science ®Google Scholar
• Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis.22(2), 111–113 (2003).
   PubMed Web of Science ®Google Scholar
• Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses46(5–6), 233–236 (2003).
   PubMed Web of Science ®Google Scholar
• Das S, Saha R, Dar SA, Ramachandran VG. Acremonium species: a review of the etiological agents of emerging hyalohyphomycosis. Mycopathologia.170(6), 361–375 (2010).
   PubMed Web of Science ®Google Scholar
• Schinabeck MK, Ghannoum MA. Human hyalohyphomycoses: a review of human infections due to Acremonium spp., Paecilomyces spp., Penicillium spp., and Scopulariopsis spp. J. Chemother.15(Suppl. 2), 5–15 (2003).
   PubMed Web of Science ®Google Scholar